Hubei Guangji Pharmaceutical Co Ltd - Asset Resilience Ratio
Hubei Guangji Pharmaceutical Co Ltd (000952) has an Asset Resilience Ratio of 5.37% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000952 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2011)
This chart shows how Hubei Guangji Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Hubei Guangji Pharmaceutical Co Ltd (000952) total assets.
Liquid Assets Composition Over Time
This chart breaks down Hubei Guangji Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Hubei Guangji Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥110.00 Million | 5.37% |
| Total Liquid Assets | CN¥110.00 Million | 5.37% |
Asset Resilience Insights
- Limited Liquidity: Hubei Guangji Pharmaceutical Co Ltd maintains only 5.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hubei Guangji Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hubei Guangji Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.33% |
|
AbbVie Inc
NYSE:ABBV |
Drug Manufacturers - General | 0.02% |
|
Merck & Company Inc
NYSE:MRK |
Drug Manufacturers - General | 0.22% |
|
AstraZeneca PLC
MX:AZNN |
Drug Manufacturers - General | 0.03% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 0.06% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
Annual Asset Resilience Ratio for Hubei Guangji Pharmaceutical Co Ltd (1999–2011)
The table below shows the annual Asset Resilience Ratio data for Hubei Guangji Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2011-12-31 | 0.00% | CN¥42.25K ≈ $6.18K |
CN¥1.51 Billion ≈ $220.47 Million |
-1.33pp |
| 2006-12-31 | 1.34% | CN¥10.50 Million ≈ $1.54 Million |
CN¥785.02 Million ≈ $114.87 Million |
+0.20pp |
| 2005-12-31 | 1.13% | CN¥10.00 Million ≈ $1.46 Million |
CN¥882.44 Million ≈ $129.13 Million |
+0.04pp |
| 2004-12-31 | 1.10% | CN¥10.00 Million ≈ $1.46 Million |
CN¥911.95 Million ≈ $133.45 Million |
-0.17pp |
| 2003-12-31 | 1.27% | CN¥11.00 Million ≈ $1.61 Million |
CN¥866.94 Million ≈ $126.86 Million |
-2.43pp |
| 2000-12-31 | 3.70% | CN¥25.00 Million ≈ $3.66 Million |
CN¥676.22 Million ≈ $98.95 Million |
-0.93pp |
| 1999-12-31 | 4.62% | CN¥30.00 Million ≈ $4.39 Million |
CN¥648.78 Million ≈ $94.94 Million |
-- |
About Hubei Guangji Pharmaceutical Co Ltd
Hubei Guangji Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical raw materials, pharmaceutical preparations, and feed additives in China and internationally. The company also exports its products. Hubei Guangji Pharmaceutical Co., Ltd. was founded in 1969 and is based in Wuxue, China.